HCV Treatment
EASL 2012: International Liver Congress Focuses on Hepatitis C Treatment, Metabolic Liver Disease
- Details
- Category: HCV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Liz Highleyman
The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) brought together more than 9000 participants this week in Barcelona to discuss the latest research in the field of liver disease.
This year's International Liver Congress is the largest to date, largely reflecting an increased interest in hepatitis C treatment spurred by the development of direct-acting antiviral (DAA) agents.
EASL 2012: Interferon Lambda as Effective as Alfa for Hepatitis C but with Much Better Safety Profile
- Details
- Category: HCV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Michael Carter
A new form of pegylated interferon, interferon lambda, is associated with significantly fewer side effects than the standard form of the drug, interferon alfa, in a study conducted in patients with easier to treat hepatitis C genotypes 2 and 3, researchers reported at the 47th International Liver Congress (EASL 2012) in Barcelona.
New VA and TAG Fact Sheets on Boceprevir and Telaprevir for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 13 April 2012 00:00
- Written by Liz Highleyman
The U.S. Department of Veterans Affairs (VA) and the Treatment Action Group (TAG) have produced new fact sheets with information about the new hepatitis C virus (HCV) protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek).
EASL International Liver Congress Starts This Week in Barcelona
- Details
- Category: HBV Treatment
- Published on Tuesday, 17 April 2012 00:00
- Written by Liz Highleyman
The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) takes place this week, April 18-22, in Barcelona. HIVandHepatitis.com will be on site to provide breaking news and analysis.
IRES Inhibitor Discovery May Offer New Way to Halt Hepatitis C Replication
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 20 March 2012 00:00
- Written by Press Release
Researchers have discovered the structure of a molecule from a class of compounds called benzimidazoles that can attach itself to the internal ribosome entry site (IRES) in the genetic material of hepatitis C virus (HCV) and stop its replication, according to a report in the March 19, 2012, advance online edition of Proceedings of the National Academy of Sciences USA.
More Articles...
- CROI 2012: Studies Look at Interactions Between New Hepatitis C Drugs and HIV Antiretrovirals
- Phase 3 Trials Now Testing HCV Drug TMC435 in Genotype 1 Non-responders and Genotype 4 Patients
- CROI 2012: HIV/HCV Coinfection News from CROI 2012 [VIDEO]
- CROI 2012: Interactions between HCV Drug Daclatasvir and HIV Antiretrovirals Are Minimal or Manageable
Web Design and Development by